Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more


(Plasmid #69358)


Item Catalog # Description Quantity Price (USD)
Plasmid 69358 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Currently unavailable outside the U.S.

This material is available to academics and nonprofits only.


  • Vector backbone
  • Backbone manufacturer
    Andrew Ball, University of Alabama at Birmingham
  • Backbone size w/o insert (bp) 3077
  • Total vector size (bp) 7977
  • Vector type

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
  • Growth Strain(s)
  • Copy number


  • Gene/Insert name
    3E5E luciferase minigenome
  • Insert Size (bp)
  • Promoter T7

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site RsRII (not destroyed)
  • 3′ cloning site XmaI (not destroyed)
  • 5′ sequencing primer ATT GTA TGG GAT CTG ATC TGG
  • 3′ sequencing primer GCC AAC TCA GCT TCC TTT CGG
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    p2,0_3E5E_luciferase was a gift from Elke Mühlberger (Addgene plasmid # 69358 ; ; RRID:Addgene_69358)
  • For your References section:

    The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals. Trunschke M, Conrad D, Enterlein S, Olejnik J, Brauburger K, Muhlberger E. Virology. 2013 Jul 5;441(2):135-45. doi: 10.1016/j.virol.2013.03.013. Epub 2013 Apr 11. 10.1016/j.virol.2013.03.013 PubMed 23582637